Halozyme Therapeutics Reports Q1 2026 Financial and Operating Results
Halozyme Therapeutics, Inc. (HALO) conducted its First Quarter 2026 Financial and Operating Results conference call on May 11, 2026. The event featured key company executives, including President and CEO Dr. Helen Torley, who provided updates on the company's business operations and strategic developments. David Ramsay, serving as Interim Chief Financial Officer, reviewed the financial results for the quarter and outlined the company's future outlook. Tram Bui, Head of Investor Relations and Corporate Communications, facilitated the session and directed participants to supplementary materials available on the investor relations website. The call included a question-and-answer segment with analysts from major financial institutions such as Citizens JMP Securities, TD Cowen, Wells Fargo Securities, Leerink Partners, Morgan Stanley, Goldman Sachs, JPMorgan Chase, and Evercore ISI. As a standard corporate earnings release, the discussion included forward-looking statements and references to risk factors detailed in SEC filings. This transcript serves as a primary source for investors and stakeholders seeking detailed insights into Halozyme's recent performance, financial health, and operational trajectory for the beginning of the 2026 fiscal year.
Wire timeline
Halozyme Therapeutics Reports Q1 2026 Financial and Operating Results
Halozyme Therapeutics, Inc. (HALO) conducted its First Quarter 2026 Financial and Operating Results conference call on May 11, 2026. The event featured key company executives, including President and CEO Dr. Helen Torley, who provided updates on the company's business operations and strategic developments. David Ramsay, serving as Interim Chief Financial Officer, reviewed the financial results for the quarter and outlined the company's future outlook. Tram Bui, Head of Investor Relations and Corporate Communications, facilitated the session and directed participants to supplementary materials available on the investor relations website. The call included a question-and-answer segment with analysts from major financial institutions such as Citizens JMP Securities, TD Cowen, Wells Fargo Securities, Leerink Partners, Morgan Stanley, Goldman Sachs, JPMorgan Chase, and Evercore ISI. As a standard corporate earnings release, the discussion included forward-looking statements and references to risk factors detailed in SEC filings. This transcript serves as a primary source for investors and stakeholders seeking detailed insights into Halozyme's recent performance, financial health, and operational trajectory for the beginning of the 2026 fiscal year.
All Articles on Seeking Alpha